STADA and Bio-Thera Receive EU Approval for Gotenfia Biosimilar to Simponi
Feb 13, 2026
The European Commission has approved Gotenfia (golimumab), a biosimilar to Simponi developed by Bio-Thera and marketed by STADA, for chronic inflammatory autoimmune diseases across the EU and EEA.